The therapeutics of possible underlying mechanisms are the improvement of the tumor microenvironment through the suppression of NF-κB and subsequent cytokines such as TGF-β, IL-10, VEGF, COX-2, CCL2 and CCL22, and enhancement the function of transferred CD8+ T-cells (Figure 6). The gene discussed is NFKB1; the disease is neoplasm.